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Accepted 25 July 2014HLA-matched sibling donors (MSDs) have long been the
gold standard for allogeneic blood or marrow transplantation
(alloBMT), but only about 35% of patients have an HLA-
matched sibling [1]. The use of HLA-matched unrelated do-
nors (MUDs; and their accompanying donor registries)
widened the donor pool, but alloBMT was still unavailable to
many individuals, particularly those in need of rapid trans-
plantation for advanced diseases or those belonging to many
minority groups. Other alternative donor transplantation ap-
proaches, including umbilical cord blood transplantation
(UCBT) andmodern approaches to HLA-haploidentical (haplo)
alloBMT, have made donors available to nearly all patients
who might require alloBMT [2-5]. However, it has been un-
clear whether any of these approaches can produce outcomes
truly similar to those seen with MSD alloBMT. The report by
Raiola et al. [6] in this current issue of Biology of Blood and
Marrow Transplantation, detailing the San Martino Hospital’s
collective institutional experience from 2006 to 2012 of MSD
and four alternative donor approaches to alloBMT, suggests
there now may be clinical equipoise as to the optimal donor.
Several large registry studies have assessed comparative
outcomes between MUD and MSD alloBMT. Studies of pa-
tients transplanted from the late 1980s to early 2000s sug-
gested that transplantation using MUDs was associated with
inferior outcomes for graft-versus-host disease (GVHD),
nonrelapse mortality (NRM), disease-free survival (DFS), and
overall survival (OS) compared with those seen with MSD
alloBMT [7-9]. Furthermore, despite the theoretical potential
for augmented antitumor activity that might accompany
minor antigen HLA-mismatching, relapsewas not lower after
MUD allografting [7-9]. Fortunately, outcomes for MUD
alloBMT have improved over time likely as a result of, among
other factors, improved HLA-typing [10], better supportive
care, and the use of antithymocyte globulin [11]. Outcomes
for MUD allografting now appear comparable with those
seen with MSD alloBMT, with the exception of higher in-
cidences of GVHD with MUDs [12-14].
Similarly, several retrospective studies have compared
UCBT with MSD or MUD alloBMT. HLA-mismatched UCBT has
been consistently associated with delayed engraftment but
similar DFS and OS when compared with MUD and/or HLA-
mismatched unrelated donor alloBMT [15-20]. Effects on
GVHD, NRM, and relapse have been inconsistent between
studies, but most suggested that UCBT was associated withDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.05.029.
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http://dx.doi.org/10.1016/j.bbmt.2014.07.029higher NRM but lower GVHD and relapse. In comparisons of
UCBT with MSD alloBMT, one study showed similar survival
outcomes for individuals  10 years old treated with high-
dose total body irradiation [16], whereas another study in
acute myelogenous leukemia patients 50 years old showed
inferior DFS with UCBT that became similar to MSD and MUD
alloBMT after adjustment in multivariate analysis [20].
Early studies of HLA-mismatched related donors were
met with unacceptably high rates of severe acute GVHD and
graft failure, thus resulting in comparatively poor survival
[21]. However, modern approaches to haplo alloBMT,
including T celledepleted “mega-dose” CD34þ allografts [3],
granulocyte colony-stimulating factoremodulated allografts
followed by aggressive pharmacologic prophylaxis [4], and
post-transplantation cyclophosphamide (PTCy) [5,22,23],
have successfully overcome the challenges encountered in
these initial studies. When compared with UCBT in parallel
phase II studies using reduced-intensity conditioning, haplo
alloBMT with PTCy was associated with improved engraft-
ment, lower severe acute and chronic GVHD, and lower NRM
[2]. However, relapse was higher after haplo alloBMT with
PTCy, leading to similar progression-free survival and OS. In
retrospective comparisons with MSD or MUD allografting,
haplo alloBMTwith PTCy was associated with similar rates of
acute GVHD, NRM, relapse, DFS, and OS as well as lower
chronic GVHD in 1 study of a heterogeneous group of he-
matologic malignancies [24], whereas a study of Hodgkin
lymphoma patients showed lower rates of chronic GVHD,
NRM, and relapse after haplo alloBMT [25].
The report by Raiola et al. [6] is unique in providing a
comprehensive evaluation of 5 different donor types used at
the same institution over the same time period (2006 to
2012). All 5 groups received cyclosporine-based GVHD pro-
phylaxis, although antithymocyte globulin also was used for
MUD, HLA-mismatched unrelated donor, and intraosseous
UCBT, and PTCy was used for haplo alloBMT. The algorithm
used by the San Martino Hospital actually provided haplo
alloBMT as a safety net available only to those patients for
whom other donor types were not available within a time
period appropriate for their disease state. Therefore, patients
receiving haplo alloBMT were the most likely to have
advanced phase disease at alloBMT. Even so, DFS and OS
were similar for all 5 groups, with haplo alloBMT patients
actually having the highest DFS and OS rates. These favorable
outcomes in haplo alloBMT were due to this group having
the lowest rates of NRM, grades II to IV acute GVHD, and
chronic GVHD as well as relapse rates comparable with other
donor types. Notably, immune reconstitution in haplo
alloBMT patients was second only toMSD alloBMT, and haplo
alloBMT patients had the highest rate of cyclosporine
discontinuation by 1 year. Although survival outcomes were
statistically similar between UCBT and other groups, the use
of UCB grafts compared with MSDs was a negative predictor
of OS in multivariate analysis. Overall, the authors concluded
that alloBMT using haplo or MUD donors yields comparable
survival with MSDs, consistent with previously published
results [23,24].
C.G. Kanakry, L. Luznik / Biol Blood Marrow Transplant 20 (2014) 1461e14641464Although these analyses may be confounded, as all retro-
spective analyses are, with differences in the transplantation
approaches and patient characteristicswithin each treatment
cohort, these results questionwhether MSD alloBMT is really
still superior to other donor alloBMT approaches. In fact, the
SanMartinoHospital groupuses haplo donors as its preferred
approach to treating active/relapsed acute leukemia [26].
Nevertheless, amajor unresolvedquestion is howmuchof the
similarity in outcomes seen in this study are related to other
elements of the transplantation platform. Relapse seen in
PTCy-treatedpatients in this study is lower than that reported
with reduced-intensity conditioning haplo alloBMT with
PTCy [2,22,23], questioning whether relapse is really higher
after PTCy and whether more intensive conditioning may
overcome any potential for higher relapse. Furthermore,
isolating the effect of haplo donors in the transplantation
platform is essential, and thus a direct comparison of haplo
bonemarrow transplantation using PTCywithMSD andMUD
bone marrow transplantation using PTCy [27,28] would be
illuminating. Even so, the results by Raiola et al. suggest that
alternative donor strategies currently may provide outcomes
similar to those seen using MSDs and the term “alternative”
may no longer be applicable.
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